A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
This early-stage clinical trial is investigating a new treatment, VERVE-102, for individuals who have very high cholesterol, either due to a genetic condition called Familial Hypercholesterolemia (HeFH) or because they have developed coronary artery disease at a younger age. The main goal of this first study is to check the safety of VERVE-102 when given as a single dose. VERVE-102 uses advanced gene-editing technology to target a specific gene in the liver, which is hoped to reduce the levels of "bad" cholesterol (LDL-C) in the blood. Researchers will also look at how the body responds to the treatment and if it starts to lower cholesterol levels. This is a crucial step in developing potential new ways to manage very high cholesterol.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is exploring a new and innovative treatment known as VERVE-102. It's designed for people who have very high cholesterol that is difficult to manage. Specifically, the study is for those with Heterozygous Familial Hypercholesterolemia (often called HeFH), which is a inherited condition causing extremely high cholesterol from a young age, or those who have developed coronary artery disease (heart problems where blood vessels are narrowed) prematurely.
VERVE-102 works differently from current cholesterol-lowering medications. It uses a cutting-edge technique called 'base-editing' directly in the liver. The idea is to switch off a specific gene called PCSK9. By reducing the activity of this gene, the body should then naturally lower the amount of 'bad' cholesterol (known as LDL-C) circulating in the blood. Managing LDL-C is vital for reducing the risk of heart disease and strokes.
Because this is a very new type of treatment, this first study (Phase 1b) is mainly focused on safety. Researchers will be giving a single dose of VERVE-102 to participants and carefully monitoring them. They will be looking for any side effects and also observing if the treatment starts to show its intended effect on cholesterol levels. This research is a vital step in trying to find new and potentially very effective ways to help people living with challenging high cholesterol conditions.
النقاط الرئيسية
- Tests a new gene-editing treatment (VERVE-102) for high cholesterol.
- Aims to help people with genetic high cholesterol or early heart disease.
- Main goal is to check the safety of this new treatment method.
- Uses a single dose of the treatment in a first-stage study.
- Could offer a new way to lower 'bad' cholesterol (LDL-C).
من قد يكون مؤهلاً؟
To be considered for this study, you would need to be an adult between 18 and 70 years old. You must also have either a confirmed diagnosis of Heterozygous Familial Hypercholesterolemia (a genetic condition causing high cholesterol) or have been diagnosed with coronary artery disease (heart conditions) at a younger age.
There are certain reasons why you might not be able to participate. For example, if you have a more severe form of Familial Hypercholesterolemia (called Homozygous), or if you have a history of serious liver problems. Also, if you are currently taking certain types of powerful cholesterol-lowering medications (called PCSK9 inhibitors) or have taken them recently, you might not be eligible.
Finally, the research team will do medical tests, and if any of your results are significantly outside the normal range, as defined by the study guidelines, you may not be able to join. These criteria are put in place to ensure the safety of all participants.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك بين 18 و 70 سنة؟
- Do you have Familial Hypercholesterolemia (HeFH) OR premature coronary heart disease?
- Do you have a history of serious liver problems?
- Are you currently taking certain strong cholesterol medications (PCSK9 inhibitors)?
- Are your routine blood tests usually within a healthy range?
ماذا يتضمن المشاركة؟
If you are eligible and choose to take part in this study, you would receive a single dose of the study drug, VERVE-102. This is an 'open-label' study, which means both you and the study team will know you are receiving the active treatment. You will have a number of visits to the clinic for health checks, blood tests, and scans. These appointments are crucial for monitoring your health, checking for any side effects, and seeing how the treatment is affecting your cholesterol levels. The total duration of your participation, including all follow-up visits, would be explained in full by the study team.
المخاطر والفوائد المحتملة
المواقع (27)
- Clinical Study Centerالرمز البريدي المؤكددوثان، الولايات المتحدة· التوظيف
- Clinical Study Centerالرمز البريدي المؤكدبومونا، الولايات المتحدة· التوظيف
- Clinical Study Centerالرمز البريدي المؤكدبوكا راتون، الولايات المتحدة· التوظيف
- Clinical Study Centerالرمز البريدي المؤكدجاكسونفيل، الولايات المتحدة· التوظيف
- Clinical Study Centerالرمز البريدي المؤكدوينتر بارك، الولايات المتحدة· التوظيف
- Clinical Study Centerالرمز البريدي المؤكدإنديانابوليس، الولايات المتحدة· التوظيف
- Clinical Study Centerالرمز البريدي المؤكدHigh Point, United States· التوظيف
- Clinical Study Centerالرمز البريدي المؤكدفيلادلفيا، الولايات المتحدة· التوظيف
- Clinical Study Centerالرمز البريدي المؤكدDeSoto, United States· التوظيف
- Clinical Study Centerالرمز البريدي المؤكدRenton, United States· التوظيف
- Clinical Study Centerالرمز البريدي المؤكدأديلايد، أستراليا· التوظيف
- Clinical Study Centerالرمز البريدي المؤكدملبورن، أستراليا· التوظيف
أسئلة شائعة
What is Familial Hypercholesterolemia (FH)?
FH is an inherited condition that causes very high levels of 'bad' cholesterol (LDL-C) from birth, leading to a higher risk of early heart disease.
What is 'base-editing' technology?
Base-editing is a very precise gene-editing technique that targets and changes a single 'letter' in our DNA code. In this study, it aims to adjust a specific gene in the liver.
What does a 'single-ascending dose' study mean?
It means participants receive one dose of the treatment. 'Ascending' often refers to different groups receiving slightly higher doses, to find out which dose is safest and most effective.
Will I know if I'm getting the actual treatment?
Yes, this is an 'open-label' study, meaning everyone taking part will receive VERVE-102, and both you and the research team will know this.
Why is lowering 'bad' cholesterol important?
Lowering 'bad' cholesterol (LDL-C) helps to reduce the build-up of fatty deposits in your arteries, which significantly lowers your risk of heart attacks and strokes.
كيفية معرفة المزيد
أسئلة التجارب أو أسئلة المشاركة: 1-877-CTLILLY (1-877-285-4559) أو
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.